Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need. In this open-label phase 2 study (ClinicalTrials.gov identifier: NCT02953678), patients aged at least 12 ye...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Jagasia, Madan, Perales, Miguel-Angel, Schroeder, Mark A., Ali, Haris, Shah, Nirav N., Chen, Yi-Bin, Fazal, Salman, Dawkins, Fitzroy W., Arbushites, Michael C., Tian, Chuan, Connelly-Smith, Laura, Howell, Michael D., Khoury, H. Jean
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229262/
https://ncbi.nlm.nih.gov/pubmed/32160294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020004823
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller